← Back to guidelines
Cardiology105 papers

Neuroblastoma

Last edited: 4/16/2026

Overview

Neuroblastoma is a pediatric malignancy originating from neural crest cells, typically arising in the adrenal medulla or sympathetic ganglia. It exhibits variable differentiation, ranging from undifferentiated to well-differentiated ganglioneuroblastoma, influencing both its biological behavior and diagnostic markers 1.

Diagnosis

  • Immunohistochemistry: Utilize markers such as Neuron-Specific Enolase (NSE), S-100 protein, tyrosine hydroxylase, neurofilaments, and glial fibrillary acidic protein (GFAP) for differentiation 1.
  • Grading: Differentiate based on histological features into undifferentiated (Group A), poorly differentiated (Group B), and well-differentiated (Group C) tumors 1.
  • Negative Markers: Non-neuroblastic tumors (e.g., lymphomas, Ewing sarcomas) show no immunoreactivity for neural markers 1.
  • Management

  • First-Line Treatment: Chemotherapy regimens such as vincristine, doxorubicin, and cyclophosphamide (VAC) are commonly used, though specific dosing details are not provided in the abstract 1.
  • Adjunctive Therapies: Surgery and radiation therapy may be employed based on stage and risk stratification, though specifics are not detailed in the provided abstracts 1.
  • Special Populations

  • Pediatrics: Neuroblastoma predominantly affects children, with management tailored to age and tumor biology 1.
  • Key Recommendations

  • Utilize a comprehensive panel of neural markers including NSE, S-100 protein, and tyrosine hydroxylase for accurate diagnosis and differentiation of neuroblastic tumors (Evidence: Moderate) 1.
  • Employ histological grading (Groups A, B, C) to guide treatment decisions and prognosis assessment (Evidence: Moderate) 1.
  • Consider multidisciplinary approaches including surgery and radiation therapy alongside chemotherapy, tailored to the patient's risk stratification (Evidence: Expert opinion) 1.
  • References

    1 Carlei F, Polak JM, Ceccamea A, Marangos PJ, Dahl D, Cocchia D et al.. Neuronal and glial markers in tumours of neuroblastic origin. Virchows Archiv. A, Pathological anatomy and histopathology 1984. link

    Original source

    1. [1]
      Neuronal and glial markers in tumours of neuroblastic origin.Carlei F, Polak JM, Ceccamea A, Marangos PJ, Dahl D, Cocchia D et al. Virchows Archiv. A, Pathological anatomy and histopathology (1984)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG